Tirzepatide Compound Price 2026: Pricing Breakdown & Comparison
Compare written compounded tirzepatide quotes by prescribed quantity, ongoing fees and discard dates, alongside FDA-approved payment options and compounding limits.
Compare actual quotes, not unsupported market averages
Compare the exact product, strength, 28-day quantity and total paid amount. A clinic membership may exclude medication, laboratory work, visits, shipping or supplies. Introductory pricing may differ from ongoing fills. Do not assume a flat fee at every strength, fixed percentage savings versus retail, or that a higher price buys a verified quality tier. Request a written itemized quote and cancellation/refund terms before paying. When reviewing quotes, our GLP-1 Price Check directory can help organize upfront and ongoing program costs.
There is no single national compounded tirzepatide price or verified “budget” versus “quality” price tier. Check offers on the provider’s own current terms. The lowest price must still refer to a lawful, clinically appropriate prescription and a named dispensing pharmacy. For broader online weight-management care, SurpassMD describes its program and assessment process.
Read the dose, concentration and quantity separately
Milligrams describe drug amount; mg/mL describes concentration; milliliters describe liquid volume. A concentration alone does not tell you the monthly quantity or price. Ask how many prescribed weekly doses the vial contains, which syringe and volume the pharmacist intends, and what happens to the price if the prescription changes. Do not assume all strengths have one flat fee or select concentration to save money without the pharmacist.
Mounjaro starts at 2.5 mg once weekly; further 2.5 mg increases require additional glycemic need and at least four weeks at the current dose. Its maximum is 15 mg weekly in adults and 10 mg in pediatric patients. Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg; later increases require at least four weeks at a dose and consideration of response and tolerability. Weight-management maintenance options are 5, 10 or 15 mg; OSA maintenance is 10 or 15 mg. The maximum is not a goal for everyone. Use the Mounjaro label or Zepbound label for the prescribed presentation.
What the quoted total should include
| Cost item | What to confirm |
|---|---|
| Medication | Exact product, strength, concentration if compounded, quantity and days supplied |
| Clinical care | Initial visit, follow-up, refills, and whether medication is separate |
| Supplies and delivery | Correct syringes or needles, delivery conditions, shipping and replacement policy |
| Ongoing commitment | Renewal amount, dose-related changes, cancellation and unused-supply refunds |
A “monthly” charge may buy a calendar month, 28 days of medication, or a membership with medication billed separately. A first-fill discount is not the maintenance price. Ask whether additional testing is clinically required and charged separately; a glucagon kit is not a routine supply fee for every tirzepatide user.
Compare approved-product payment options fairly
Use Zepbound manufacturer terms and Mounjaro manufacturer terms for the actual product. Commercial copay offers do not mean an uninsured person pays the advertised minimum. Zepbound also has a separate self-pay pathway. Neither brand has the same universal price or guaranteed savings percentage as the other. Lilly Cares’ medication list does not list Mounjaro or Zepbound in this review; LillyDirect should not be described as a free tirzepatide assistance program.
Price and accreditation do not establish equivalence
FDA-approved and compounded medicines have different evidence and oversight. FDA’s GLP-1 safety guidance explains that compounded products are not reviewed before marketing for safety, effectiveness or quality. Pharmacy licensing, accreditation, price and customer reviews do not establish equivalence to the approved product or guarantee a particular vial’s potency or sterility. Research-use vials are not prescription medication for home treatment.
Compounding is a patient-specific medical decision, not an FDA-approved generic alternative. FDA’s current compounding policy distinguishes section 503A prescriptions and restrictions on making essentially copies from the separate section 503B bulk-substance and copy requirements. A prescriber-documented significant difference for an identified patient matters under 503A; cost or a prescription alone does not remove federal restrictions. Shortage-related enforcement discretion for tirzepatide ended in 2025. The April 2026 503B proposal is a proposal, not a final blanket prohibition on all compounding.
Verify an active pharmacy license, the actual accreditation if claimed, pharmacist availability and product-specific instructions. Ask how quality complaints and suspected adverse events are handled. A testing report, accreditation badge or higher fee is not a guarantee against contamination, dosing error or variable potency.
Bulk purchases, beyond-use dates and ongoing cost
For compounded GLP-1 vials containing multiple doses, FDA advises discarding the vial within 28 days after first use even if the compounder says it can be used longer; an earlier beyond-use date still applies. Use a fresh sterile needle and syringe each time. This is distinct from the presentation-specific instructions for approved Mounjaro or Zepbound. Ask the dispensing pharmacist to reconcile the prescribed milligrams, concentration, measured volume, storage and discard dates before use. Do not use a general peptide calculator or research-vial mixing guide as the prescription.
Calculate usable prescribed doses before prepaying. A multi-month quantity is not automatically safe or economical when part must be discarded after opening or the clinician changes treatment. Ask about separate unopened vials, their individual beyond-use dates, and refund terms. Do not buy extra on an assumed monthly escalation schedule.
Frequently Asked Questions
Obtain an itemized current quote for the exact prescription and quantity. This review does not establish a national monthly price or universal savings percentage; compare it with available approved-product payment options.
It can be. Check the actual quantity, strength, concentration, days supplied and renewal terms; a flat fee across all doses is not a market-wide rule.
Only the written offer can establish that. Verify medication, visits, follow-up, supplies, shipping, laboratory work if needed and cancellation/refund terms separately.
A current lowest-price pharmacy cannot be identified from a general market range. Compare current written offers after establishing the clinical need, lawful pathway, pharmacy license and actual product supplied.
It is an accreditation claim to verify with the accreditor. It does not make a compounded medicine FDA-approved or guarantee a vial’s sterility or potency. No fixed accreditation price premium is established.
Compare the actual compound quote with the exact approved product and presentation, insurance eligibility or self-pay terms. Neither list-price comparisons nor insured copay minimums describe every patient’s cost.
Not automatically. A telehealth headline may exclude medication or charge separate care fees. Verify the actual medication offer and check each provider’s own current terms.
Only if the prescribed doses remain usable under storage and discard limits and the commitment fits the clinical plan. FDA advises discarding compounded multi-dose GLP-1 vials within 28 days after first use even if directions say longer; an earlier beyond-use date controls. Approved brand instructions are separate.
Shortage-related enforcement discretion ended in 2025. Current federal 503A/503B conditions and essentially-copy restrictions still apply; the 2026 503B exclusion announcement reviewed here is a proposal, not a final blanket ban.
Confirm the active license, actual dispensing pharmacy, prescription instructions, claimed accreditation, product-specific quality information and a reachable pharmacist. Price, reviews or a testing badge cannot guarantee equivalence or eliminate contamination and dosing risks.